Navigation Links
Tengion Presents New Data in Nine Posters and Two Oral Presentations at TERMIS North America Annual Meeting
Date:12/7/2010

a purpose to which they are poorly suited, procure donor organs or administer anti-rejection medications. An initial clinical trial is ongoing for the Company's lead product candidate, the Neo-Urinary Conduit™, an autologous implant that is intended to catalyze regeneration of native-like bladder tissue for bladder cancer patients requiring a urinary diversion following bladder removal.  The Company's lead preclinical program is the Neo-Kidney Augment™, which is designed to delay or prevent the need for dialysis or transplantation in patients at risk for kidney failure.  Tengion has also applied its technology in two Phase II clinical trials for Tengion's Neo-Bladder Augment™ for the treatment of neurogenic bladder.  Tengion has worldwide rights to its product candidates. For more information, please visit www.tengion.com.

Forward-Looking Statements

Certain statements set forth above may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to the Company's: (i) plans to develop and commercialize its product candidates, including the Neo- Kidney Augment and the Neo-Urinary Conduit; and (ii) expectations regarding ongoing and planned preclinical studies and clinical trials. Although Tengion believes that these statements are based upon reasonable assumptions within the bounds of its knowledge of its business and operations, there are a number of factors that may cause actual results to differ from these statements. For instance there can be no assurance that: (i) the Company will be able to obtain the capital it needs to develop its product candidates or continue as a going concern; (ii) the Company will be able to successfully enroll patients in its clinical trials, including its Phase I clinical trial for the Neo-Urinary Conduit; (iii) patients enrolled in the Company's clinical t
'/>"/>

SOURCE Tengion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
2. Tengion Launches Third Phase 2 Clinical Trial of Regenerated Human Bladder
3. Preclinical Data Demonstrate Ability to Regenerate an Entire Bladder With Tengion Neo-Bladder Replacement(TM)
4. Tengion Scientists Publish Key Preclinical Findings Demonstrating the Benefits of Organ Regeneration Vs. Repair
5. Tengion Appoints Sunita B. Sheth, M.D., Chief Medical Officer
6. Tengion Presents New Data Demonstrating Functional Regeneration in a Diabetic Chronic Kidney Failure Model at the International Society for Cellular Therapy
7. Tengion Announces First Implantation of Neo-Urinary Conduit™ in Initial Clinical Trial in Patients with Bladder Cancer
8. Tengion Reviews Pipeline Progress at First Analyst and Investor Meeting; Strategic & Clinical Updates Provided for Regenerative Medicine Programs
9. Tengion Provides Business Update and Reports Third Quarter 2010 Financial Results
10. Tengion Advances Clinical Trial for Neo-Urinary Conduit™ in Bladder Cancer Patients
11. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... Aug. 27, 2015  BioElectronics Corporation (OTC Pink: BIEL), the ... three abstracts featuring the use of ActiPatch®, its novel ... th Congress of the European Pain Federation EFIC®, ... September 2015. The Company will also be exhibiting at ... Gianluca Bagnato , department clinical and experimental rheumatology from ...
(Date:8/27/2015)... Aug. 27, 2015   Americord Registry , a ... and placenta tissue banking company, announced today ... e-commerce website. This new website makes the expecting parent,s ... interactive shopping cart and checkout process. Logo ... blood banking websites make this service difficult to purchase ...
(Date:8/27/2015)... 27, 2015  Zimmer Biomet Holdings, Inc. (NYSE and ... that it will be participating in the Goldman Sachs ... Sachs offices in London on ... Founded in 1927 and headquartered in Warsaw, ... in musculoskeletal healthcare.  We design, manufacture and market orthopaedic ...
Breaking Medicine Technology:BioElectronics Selected to Present its Pain Research and Devices at the European Pain Federation Conference 2Cord Blood Bank Revolutionizes Process of Online Cord Blood Banking 2
... Symmetry Medical Inc. (NYSE: SMA ), a leading ... and other medical markets, announced today that it has entered ... November 3, 2010.  The credit facility includes an "accordion feature" ... million. The credit facility has a term of five years. ...
... Nov. 3, 2010 Aethlon Medical, Inc. (OTC ... in developing therapeutic filtration devices to address infectious ... present tomorrow at the at the Singular Research ... Los Angeles. (Photo:   http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b ) ...
Cached Medicine Technology:Symmetry Medical Closes $200 Million Credit Facility 2Symmetry Medical Closes $200 Million Credit Facility 3Aethlon Medical to Present at the Singular Research Fifth Annual 'Best of the Uncovereds Conference' 2Aethlon Medical to Present at the Singular Research Fifth Annual 'Best of the Uncovereds Conference' 3Aethlon Medical to Present at the Singular Research Fifth Annual 'Best of the Uncovereds Conference' 4
(Date:8/27/2015)... (PRWEB) , ... August 28, 2015 , ... This new ... ensure that patients are always scheduled for the next visit, their authorizations are in ... here . , According to Jason Barnes, COO for Genesis Chiropractic Software, growing a ...
(Date:8/27/2015)... Mesa, CA (PRWEB) , ... August 27, 2015 , ... ... to get help, leaving weeks or months later, relapsing and returning again, all at ... under the influence while in sober living homes or soon after leaving facilities who ...
(Date:8/27/2015)... Los Angeles, CA (PRWEB) , ... August 27, 2015 , ... ... Diabetes Association and the American Heart Association have released new guidelines to educate doctors ... that the last update to these particular guidelines came in 2007, so the new ...
(Date:8/27/2015)... ... 27, 2015 , ... In mid-May, Logistics Trust, Inc. (“Logistics ... launch of its Doobster platform, a HIPAA-compliant mobile application that allows medical marijuana ... phones and tablets. Well, Doobster, “The App That Delivers!” is here! ...
(Date:8/27/2015)... ... August 27, 2015 , ... The Naderi Center is proud to announce ... cutting-edge, noninvasive procedure to improve submental fat. The first and only Food and ... surgery. Dr. Kulak is the only Board Certified surgeon in the D.C., Maryland, ...
Breaking Medicine News(10 mins):Health News:A New Webinar Teaches Chiropractors How to Use Compliance Alerts to Manage Patient Relationships 2Health News:National Screenings of Documentary Indicate Burgeoning Questions about the Effectiveness of Addiction Treatment Facilities 2Health News:National Screenings of Documentary Indicate Burgeoning Questions about the Effectiveness of Addiction Treatment Facilities 3Health News:Article on New Diabetic Care Guidelines Shines Brightly on Weight Loss Surgery, notes Beverly Hills Physicians 2Health News:Article on New Diabetic Care Guidelines Shines Brightly on Weight Loss Surgery, notes Beverly Hills Physicians 3Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 2Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 3Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 4Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 5Health News:Noninvasive Double Chin Elimination Now Available in Herndon and Chevy Chase 2Health News:Noninvasive Double Chin Elimination Now Available in Herndon and Chevy Chase 3
... under the Revised National TB Control Programme (RNTCP) aims ... treatment and diagnostic services to all tuberculosis patients. It ... HIV-positive people are more prone to contracting tuberculosis. Hence ... plan to tackle this issue and multi-drug resistant cases. ...
... and minds of various people world over. But now it ... detox products are to be investigated by the British government. ... attention to some of their medical claims. , ,The ... based on investigations by Real Story's Doctors on a Detox ...
... attempting of suicide is high among the children of men ... the University of British Columbia and several other institutions in ... working or had worked at sawmills in British Columbia - ... ,They collected data on the men's history of employment, their ...
... for calming the nervous, can act otherwise leading ... ,Substances like diphenhydramine, which can be ... says Ursula Sellerberg, spokeswoman for the Federal Organization ... ,Diazepam, the main ingredient in valium, can ...
... new studies, researchers claim that more people could be ... cow disease than previously thought after new evidence emerged ... developing. // According to the scientists from Edinburgh a ... to pass through blood transfusions and surgical instruments, can ...
... market in Norwich is a non-referral drop-in-center aimed at people, ... after its fallen apart. // Founded in 1994, the centre ... mental health charity Rethink. The centre will be launching an ... and shallowness, that follows mental illness. ,The place is ...
Cached Medicine News:Health News:India to Implement National Action Plan against TB-HIV 2Health News:Mad Cow Disease – Worst Is Yet To com 2Health News:Bridging People’s lives, Post Upheava 2
... the first polypropylene mesh specifically designed ... directly addresses the critical issues associated ... delivers maximum visibility, enhanced maneuverability and ... through the trocar.,Visilex mesh is the ...
... technique, recommended for the treatment of ... direct inguinal hernias, provides significant advantages ... less overall dissection and is utilized ... The result is increased patient comfort, ...
... longest available wavelength with a unique flat ... efficacy. The unique flat beam profile consistently ... all targeted structures. The Lyra-I uniquely avoids ... Lyra-I patients are protected by patented continuous ...
... nonabsorbable knitted product for use in ... a highly flexible and compliant material ... surgical adaptability, along with maximal porosity ... Mesh is constructed from polyethylene terephthalate, ...
Medicine Products: